BMO Capital Markets restated their buy rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a report published on Wednesday morning. The firm currently has a $196.00 target price on the specialty pharmaceutical company’s stock.
Other analysts have also issued reports about the stock. Leerink Swann boosted their price objective on shares of Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the company a buy rating in a report on Tuesday, July 4th. Janney Montgomery Scott boosted their price target on shares of Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the stock a buy rating in a research note on Tuesday, July 4th. Deutsche Bank AG reiterated a buy rating and set a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a hold rating to a buy rating and set a $165.11 price target on the stock in a research note on Tuesday, June 27th. Finally, Royal Bank Of Canada set a $210.00 price target on shares of Jazz Pharmaceuticals PLC and gave the stock a buy rating in a research note on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $180.96.
Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up 0.07% on Wednesday, hitting $147.89. 187,044 shares of the stock were exchanged. The firm has a market cap of $8.88 billion, a PE ratio of 22.78 and a beta of 1.13. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The stock’s 50 day moving average price is $148.82 and its 200 day moving average price is $150.52.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). The company had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.67 earnings per share. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Earns Buy Rating from BMO Capital Markets” was first reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://weekherald.com/2017/09/23/jazz-pharmaceuticals-plc-jazz-earns-buy-rating-from-bmo-capital-markets.html.
In related news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $154.97, for a total value of $30,994.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The disclosure for this sale can be found here. Insiders sold 8,297 shares of company stock valued at $1,279,417 over the last ninety days. 4.30% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Toronto Dominion Bank boosted its holdings in Jazz Pharmaceuticals PLC by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 81 shares in the last quarter. US Bancorp DE boosted its holdings in Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 368 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 295 shares in the last quarter. World Asset Management Inc acquired a new position in Jazz Pharmaceuticals PLC in the first quarter valued at approximately $205,000. Finally, Gargoyle Investment Advisor L.L.C. acquired a new position in Jazz Pharmaceuticals PLC in the second quarter valued at approximately $206,000. 88.24% of the stock is owned by hedge funds and other institutional investors.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com’s FREE daily email newsletter.